NIKKEI 225
33,486.89 +165.67 (+0.50%) HANG SENG
17,049.26 +55.82 (+0.33%) CRUDE OIL
78.12 +0.26 (+0.33%) GOLD FUTURES
2,064.70 -2.40 (-0.12%) DOW
35,430.42 +13.44 (+0.04%) Bitcoin GBP
29,795.68 -263.06 (-0.88%)
Genmab A/S (0MGB.L)
- Globe Newswire
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy European Medicines Agency (EMA) validates regulatory application for epcoritamab for the same indicationThe regulatory actions are supported by data from the phase 1/2 EPCORE™ NHL-1 trial Genmab A/S (Nasdaq: GMAB) today an
- GlobeNewswire
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish tradin
- GlobeNewswire
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of Directors and employees of the Company as well as the Company’s subsidiaries and 7,651 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK
